SiBone (SIBN) – What Are Investment Firms Saying About This Stock?

SiBone (NASDAQ:SIBN) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $24.50.

A number of equities analysts have commented on the company. UBS Group lifted their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Truist Financial upped their price target on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Finally, TD Cowen raised their target price on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th.

SiBone Trading Up 2.7%

SIBN opened at $22.41 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $22.95. The firm has a market capitalization of $993.86 million, a PE ratio of -65.91 and a beta of 0.66. The company’s 50-day moving average is $19.38 and its 200 day moving average is $16.42.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The business had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. As a group, research analysts predict that SiBone will post -0.40 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SiBone news, CEO Laura Francis sold 38,006 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $20.05, for a total transaction of $762,020.30. Following the completion of the transaction, the chief executive officer owned 379,256 shares of the company’s stock, valued at $7,604,082.80. This trade represents a 9.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Anshul Maheshwari sold 1,731 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $19.50, for a total transaction of $33,754.50. Following the completion of the sale, the insider directly owned 218,235 shares in the company, valued at approximately $4,255,582.50. This trade represents a 0.79% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 224,968 shares of company stock valued at $4,368,118 in the last three months. 4.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. D.A. Davidson & CO. increased its position in SiBone by 2.8% during the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock worth $711,000 after buying an additional 1,038 shares in the last quarter. First Light Asset Management LLC lifted its holdings in SiBone by 51.8% during the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after buying an additional 2,774,795 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of SiBone by 40.3% during the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock worth $1,928,000 after purchasing an additional 33,947 shares during the period. VELA Investment Management LLC increased its stake in shares of SiBone by 7.4% in the second quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock valued at $3,282,000 after purchasing an additional 13,934 shares during the period. Finally, Corient Private Wealth LP lifted its holdings in SiBone by 119.6% in the second quarter. Corient Private Wealth LP now owns 43,946 shares of the company’s stock worth $717,000 after purchasing an additional 23,938 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.